Neuralstem, Inc. (CUR) Short Interest Update
Neuralstem, Inc. (NASDAQ:CUR) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 1,413,759 shares, an increase of 136.4% from the November 30th total of 598,032 shares. Approximately 11.3% of the company’s shares are sold short. Based on an average daily volume of 6,510,771 shares, the days-to-cover ratio is presently 0.2 days.
Shares of Neuralstem (NASDAQ:CUR) opened at $2.03 on Wednesday. Neuralstem has a 12-month low of $0.88 and a 12-month high of $6.60. The firm has a market capitalization of $30.75, a price-to-earnings ratio of -1.22 and a beta of 1.63.
Several institutional investors have recently bought and sold shares of CUR. Blair William & Co. IL increased its position in shares of Neuralstem by 171.0% during the second quarter. Blair William & Co. IL now owns 87,343 shares of the company’s stock worth $506,000 after acquiring an additional 55,115 shares during the period. Vanguard Group Inc. increased its position in shares of Neuralstem by 1.1% during the second quarter. Vanguard Group Inc. now owns 345,346 shares of the company’s stock worth $2,000,000 after acquiring an additional 3,853 shares during the period. Finally, National Asset Management Inc. increased its position in shares of Neuralstem by 9.2% during the second quarter. National Asset Management Inc. now owns 22,985 shares of the company’s stock worth $134,000 after acquiring an additional 1,937 shares during the period. 7.05% of the stock is currently owned by institutional investors and hedge funds.
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.